Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Rhea-AI Summary

Revelation Biosciences (NASDAQ:REVB) announced the cancellation of the adjourned Special Meeting of Stockholders that had been rescheduled for October 29, 2025 due to a technical difficulty that prevented stockholders from voting all of their shares.

The company set a new record date of October 29, 2025 and scheduled a new Special Meeting for December 3, 2025. Revelation will mail new proxy materials to all stockholders of record as of the new record date and urges stockholders to vote promptly upon receipt.

SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the October 15, 2025 Special Meeting of Stockholders of Revelation Biosciences, Inc. (the "Company"), which was adjourned to October 29, 2025 has been canceled due to technical difficulty outside of the Company's control with stockholders being unable to vote all of their shares. The Company has decided to cancel the adjourned Special Meeting scheduled for today, October 29, at 12pm ET and to set a new record date of October 29, 2025 for a new Special Meeting of Stockholders to take place on December 3, 2025. The Company will issue new proxy materials to all stockholders of record as of the new record date in connection with this meeting. The Company encourages all stockholders to vote their shares promptly upon receipt of the proxy materials.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contacts

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

FAQ

Why did Revelation Biosciences (REVB) cancel the adjourned Special Meeting on October 29, 2025?

The meeting was canceled because a technical difficulty prevented stockholders from being able to vote all of their shares.

What is the new record date for the Revelation Biosciences (REVB) Special Meeting?

The new record date is October 29, 2025.

When will the rescheduled Revelation Biosciences (REVB) Special Meeting take place?

The rescheduled Special Meeting is set for December 3, 2025.

Will Revelation Biosciences (REVB) send new proxy materials for the December 3, 2025 meeting?

Yes. The company will issue new proxy materials to all stockholders of record as of the new record date.

What should REVB stockholders do when they receive the new proxy materials?

Stockholders are encouraged to review the materials and vote their shares promptly upon receipt.